Q1 Earnings Forecast for BEAM Issued By Leerink Partnrs

Beam Therapeutics Inc. (NASDAQ:BEAM) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Beam Therapeutics in a research note issued on Tuesday, February 25th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($1.26) for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics’ FY2026 earnings at ($5.09) EPS.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.16. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company had revenue of $30.00 million for the quarter, compared to analysts’ expectations of $16.47 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The business’s revenue for the quarter was down 90.5% compared to the same quarter last year.

Several other research firms have also recently weighed in on BEAM. Wedbush reiterated an “outperform” rating and set a $57.00 price objective on shares of Beam Therapeutics in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Beam Therapeutics in a research report on Monday, February 3rd. Royal Bank of Canada lifted their price objective on shares of Beam Therapeutics from $24.00 to $26.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Cantor Fitzgerald raised shares of Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, January 29th. Finally, Leerink Partners raised shares of Beam Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $27.00 to $39.00 in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $47.89.

Beam Therapeutics Price Performance

NASDAQ BEAM opened at $27.89 on Thursday. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $49.50. The firm has a market capitalization of $2.31 billion, a PE ratio of -15.85 and a beta of 1.92. The company’s 50 day simple moving average is $27.19 and its 200 day simple moving average is $25.89.

Insiders Place Their Bets

In other Beam Therapeutics news, CEO John M. Evans sold 30,000 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the completion of the transaction, the chief executive officer now owns 908,659 shares of the company’s stock, valued at $24,306,628.25. The trade was a 3.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christine Bellon sold 1,241 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the transaction, the insider now directly owns 102,968 shares of the company’s stock, valued at approximately $2,541,250.24. This represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BEAM. Creative Planning increased its holdings in shares of Beam Therapeutics by 25.5% during the 3rd quarter. Creative Planning now owns 11,946 shares of the company’s stock worth $293,000 after purchasing an additional 2,424 shares during the period. Blue Trust Inc. increased its holdings in shares of Beam Therapeutics by 84.0% during the 3rd quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock worth $73,000 after purchasing an additional 1,431 shares during the period. International Assets Investment Management LLC bought a new position in shares of Beam Therapeutics during the 3rd quarter worth about $15,760,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Beam Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock worth $75,000 after purchasing an additional 524 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Beam Therapeutics by 62.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,087 shares of the company’s stock worth $394,000 after purchasing an additional 6,181 shares during the period. Institutional investors own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.